AstraZeneca Plc (AZN) and three generic-drug makers must face class-action allegations they overcharged consumers by delaying low-cost versions of the heartburn medication Nexium for six years, a judge ruled. U.S. District Judge William Young in Boston ruled today that union health plans and insurance companies can join together in pursuing antitrust claims against AstraZeneca, Teva Pharmaceutical Industries Ltd. (TEVA), Dr. Reddy’s (DRRD) Laboratories Inc. and Ranbaxy Laboratories Ltd. (RBXY) They face claims that AstraZeneca paid “substantial sums” to generic drugmakers to delay copies of Nexium for six years until May 27, 2014, which prevented prices from falling through the introduction of cheaper copies.
Help employers find you! Check out all the jobs and post your resume.
